|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.328 SEK | +0.61% |
|
+3.27% | +43.72% |
| 05-22 | Intervacc AB Completes Successful Evaluation of Us Strain of Strangles Pathogen Ahead of Clinical Trials | CI |
| 05-15 | Sweden's Intervacc Elects New Chair | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 47.97M | - | ||||
| 54.92B | |||||
| 44.31B | |||||
| 22.96B | - | ||||
| 21.12B | - | ||||
| 16.31B |
- Stock Market
- Stocks
- IVACC Stock
- Charts Intervacc AB
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
